Chinese heparin API market to account for about 80% of global demand; report

It is projected that the heparin active pharmaceutical ingredient (API) in China will achieve an additional capacity of more than 20 trillion units by 2015, when China's total capacity will exceed 30 trillion units, accounting for roughly 80% of the global demand, according to a new report.

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China's heparin products. In 2013, the live pigs raised in China could manufacture 27.9 trillion units of heparin crude products. And in first-half 2014, the live hogs in China may produce 14.09 trillion units of heparin crude products, up 5.6% on a year-on-year basis.

In 2011-2013, affected by the economic downturn in Europe and America, the global heparin preparations market continued to drop, with the sales volume of main heparin preparations brands virtually presenting decline, thus dragging down the exports of China's heparin products. In 2013, China exported around 13.68 trillion units of heparin and its salts, falling 5.9% year on year, and the figure edged down 0.6% from a year earlier to around 9.32 trillion units in January-August 2014.